Rosalind Advisors, Inc. Portfolio

Auto-discovered active 13F filer.

SEC 13F CIK: 0001622627

What is a 13F filing? Who files one and when · What 13F filings can't tell you

SmallFocusedHealth TiltHigh Turnover how tags are computed

Q3 2026 · 39 positions · Total reported value $244.66M · Top-10 concentration 74.5% · Updated 2026-11-16

Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR

Turnover: 54.8% · 9 new · 11 cut · 3 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q2 2026 → Q3 2026): +4.7% · vs SPY +2.5% · Prev Value $269.06M — last quarter positions weighted by this quarter price moves · ranking

Est. QTD Return (Q3 2026 → newest close): -5.8% · vs SPY -7.9% · Latest Value $244.66M — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking

In its Q3 2026 13F filing, Rosalind Advisors, Inc. disclosed 39 equity positions with a combined reported value of $244.66M. The filing implies a focused portfolio: its ten largest positions account for 74.5% of reported value. HoldingsHub classifies the profile as Small / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q3 2026 were DCTH ($52.71M), FENC ($33.95M), HELP ($17.06M). By sector, the heaviest allocations are Health Care 99.9%, Industrials 0.0%. Versus the prior quarter, allocation shifted toward Health Care (+5.1pp) and away from Industrials (-5.2pp).

Versus the prior quarter, Rosalind Advisors, Inc. opened 9 new positions, trimmed 11 and fully exited 3, a turnover rate of 54.8% of positions. The portfolio's overlap with the prior quarter was 71% of names.

The largest new positions opened in Q3 2026 were REPL ($13.24M), TARA ($7.32M), RCKT ($5.79M).

Of the 3 positions fully exited versus the prior quarter, the largest were CLDX ($7.44M), ELDN ($130.78K), TENX ($13.95K).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q3 2026)

  • REPL REPLIMUNE GROUP INC · $13.24M
  • TARA PROTARA THERAPEUTICS INC · $7.32M
  • RCKT ROCKET PHARMACEUTICALS INC · $5.79M
  • ABOS ACUMEN PHARMACEUTICALS INC · $2.44M
  • FEMY FEMASYS INC · $1.64M
  • GRCE GRACE THERAPEUTICS INC · $1.02M
  • QQQ INVESCO QQQ TR · $257.50K
  • BMY BRISTOL-MYERS SQUIBB CO · $84.20K

Fully Exited (vs previous quarter)

  • CLDX CELLDEX THERAPEUTICS INC NEW · prev qtr: $7.44M
  • ELDN ELEDON PHARMACEUTICALS INC · prev qtr: $130.78K
  • TENX TENAX THERAPEUTICS INC · prev qtr: $13.95K

Insider Transactions (Form 4)

Latest Rosalind Advisors, Inc. buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

Transaction date Activity Security Shares Price Filing
2026-10-13 J DELCATH SYSTEMS, INC. 27,502 — SEC filing
2026-10-13 Conversion DELCATH SYSTEMS, INC. 3,627 — SEC filing

All insider transactions →

Fund Profile

Rosalind Advisors, Inc. is an SEC-registered 13F filer. As of Q2 2026 it reported 33 US equity positions with a combined value of $269.06M. HoldingsHub carries 11 quarters of its filings (Q4 2023–Q2 2026).

Portfolio Structure

  • 33 positions · $269.06M reported value (Q2 2026)
  • Top 10 holdings = 74.1% of reported value
  • Largest position: DCTH (DELCATH SYS INC) at 15.4%
  • Average position size: $8.15M

Sector Tilt

  • Health Care 94.7%
  • Industrials 5.3%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q2 2026: 6 new, 7 added, 12 reduced, 8 exited
  • 8 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

1. Overall direction and market view: The fund is actively concentrating positions in biotech/healthcare (100% sector), with a bullish tilt on high-risk clinical-stage names (e.g., REPL, AQST) but trimming some overexposed positions (HELP, VOR, PCVX). 2. Key moves: - Added: AQST (700% share increase, +3.4% weight), REPL (new position, +5.4% weight). - Reduced: HELP (-29.1% shares, -2.1% weight), VOR (-6.1% shares, +0.3% weight), PCVX (-25.3% shares, -0.9% weight). 3. Portfolio structure: Highly active, concentrated (top 10 = 71.3%), high-risk (small-cap biotech with binary clinical outcomes), and sector-constrained (100% Health Care). 4. Per-holding one-liner: - DCTH: Delcath Systems (liver cancer drug delivery). - FENC: Fennec Pharmaceuticals (psilocybin for depression). - HELP: Cybin (psychedelic therapeutics). - SVRA: Savara (inhaled antibiotics). - REPL: Replicune Group (oncolytic virus immunotherapy). - VOR: Vor Biopharma (CAR-T for blood cancers). - MDWD: MediWound (severe burn treatment). - XFOR: X4 Pharmaceuticals (osteosarcoma drug). - AQST: Aquestive Therapeutics (orphan drug delivery). - PCVX: Vaxcyte (vaccine development). 5. Style summary: Aggressive biotech fund doubling down on high-potential clinical-stage names while trimming overextended positions.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice. · AI generated 2026-11-17 05:38

Sector Allocation

Health Care 99.9%
Other 0.1%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 3.30M $52.71M 21.54%
21.54%
Hold
2 3.19M $33.95M 13.88%
13.88%
Hold
3 1.39M $17.06M 6.97%
6.97%
Reduce
4 3.18M $16.40M 6.70%
6.70%
Hold
5 1.00M $13.24M 5.41%
5.41%
New
6 609.20K $11.62M 4.75%
4.75%
Reduce
7 749.05K $10.31M 4.22%
4.22%
Hold
8 3.21M $9.32M 3.81%
3.81%
Hold
9 2.00M $9.26M 3.79%
3.79%
Add
10 149.36K $8.50M 3.47%
3.47%
Reduce
11 2.40M $7.32M 2.99%
2.99%
New
12 3.92M $6.11M 2.50%
2.50%
Add
13 721.50K $6.01M 2.46%
2.46%
Hold
14 2.20M $5.79M 2.37%
2.37%
New
15 828.12K $4.80M 1.96%
1.96%
Hold
16 4.13M $4.80M 1.96%
1.96%
Reduce
17 548.12K $4.04M 1.65%
1.65%
Add
18 1.11M $2.76M 1.13%
1.13%
Hold
19 3.91M $2.62M 1.07%
1.07%
Hold
20 1.10M $2.44M 1.00%
1.00%
New
21 20.87K $2.07M 0.84%
0.84%
Hold
22 1.79M $1.93M 0.79%
0.79%
Add
23 759.21K $1.64M 0.67%
0.67%
New
24 280.06K $1.46M 0.60%
0.60%
Reduce
25 20.00K $1.42M 0.58%
0.58%
Reduce
26 26.52K $1.29M 0.53%
0.53%
Add
27 701.68K $1.27M 0.52%
0.52%
Hold
28 100.00K $1.07M 0.44%
0.44%
Hold
29 476.19K $1.02M 0.42%
0.42%
New
30 177.01K $932.85K 0.38%
0.38%
Reduce
31 293.60K $356.54K 0.15%
0.15%
Reduce
32 50.00K $257.50K 0.10%
0.10%
New
33 412.70K $256.88K 0.10%
0.10%
Add
34 67.51K $183.95K 0.07%
0.07%
Reduce
35 400.00K $160.00K 0.07%
0.07%
Reduce
36 618.80K $127.00K 0.05%
0.05%
Add
37 20.00K $84.20K 0.03%
0.03%
New
38 701.70K $50.00K 0.02%
0.02%
Reduce
39 10.00K $23.50K 0.01%
0.01%
New

Holdings Prediction Model

Predicts next-quarter Top-10 holdings and weights from the fund's own historical trading轨迹 (add / reduce / hold) plus each stock's price momentum and relative volume. Strictly no look-ahead: a prediction for quarter T+1 uses only data through quarter T. Weights are shares of the modelled portfolio.

The next-quarter predicted Top 10 (2026-Q4) is shown in the «Latest Q · Forecast» tab above, in the same holdings format. That view is for logged-in accounts: 3 views per day on Free, unlimited on Gold/Diamond.

Latest-Quarter Accuracy (2026-Q3)

P 70% R 70% F1 70% (modelled on 2026-Q2; 7/10 hit)

Low-confidence forecast This fund replaces about 30% of its Top-10 each quarter and backtests at F1 70% (threshold 80%). Holdings in high-turnover portfolios cannot be forecast from their own history; the figures below are illustrative.

Historical Backtest (10 quarters)

Avg precision 70% · recall 70% · F1 70% · avg rank error 2.8 · Top-10 turnover 30%

Quarter Prec. Recall F1 Predicted Top 10 Actual Top 10
2024-Q2 60% 60% 60% MYO · MDWD · OPTN · LYRA · CMPS · XERS · CYBN · ABVX · VRDN · DCTH DCTH · MYO · MDWD · OPTN · ABEO · XERS · CLRB · NSPR · CYBN · OCUL
2024-Q3 90% 90% 90% DCTH · MYO · OPTN · MDWD · CLRB · ABEO · NSPR · XERS · CYBN · OCUL DCTH · MYO · ABEO · MDWD · CYBN · XERS · VRNA · CLRB · OCUL · NSPR
2024-Q4 60% 60% 60% DCTH · MYO · MDWD · ABEO · XERS · CYBN · CLRB · VRNA · OCUL · NSPR DCTH · MYO · MDWD · CMRX · XERS · ABEO · OCUL · URGN · SVRA · FENC
2025-Q1 70% 70% 70% DCTH · MYO · MDWD · CMRX · XERS · OCUL · ABEO · URGN · SVRA · FENC DCTH · VSTM · XERS · MYO · IDYA · FENC · URGN · OCUL · ABEO · REPL
2025-Q2 70% 70% 70% DCTH · VSTM · XERS · MYO · FENC · IDYA · URGN · REPL · OCUL · VRDN DCTH · FENC · CYTK · OCUL · XERS · VRDN · VRNA · VSTM · MDWD · MYO
2025-Q3 60% 60% 60% DCTH · FENC · CYTK · OCUL · VRDN · XERS · VSTM · VRNA · RZLT · MYO DCTH · CYTK · FENC · XERS · SVRA · MDWD · VRDN · CGON · VRNA · NSPR
2025-Q4 70% 70% 70% DCTH · CYTK · FENC · SVRA · MDWD · XERS · CGON · VRDN · VRNA · NSPR DCTH · SVRA · FENC · XERS · VRDN · MDWD · ATYR · HELP · EYPT · CGON
2026-Q1 60% 60% 60% DCTH · SVRA · FENC · XERS · ATYR · MDWD · HELP · VRDN · CGON · EYPT DCTH · XERS · FENC · SVRA · PCVX · EYPT · XFOR · VOR · MDWD · VSTM
2026-Q2 90% 90% 90% DCTH · XERS · FENC · SVRA · PCVX · XFOR · EYPT · VOR · VSTM · MDWD DCTH · FENC · XERS · SVRA · VSTM · XFOR · EYPT · HELP · VOR · PCVX
2026-Q3 ★ 70% 70% 70% DCTH · FENC · XERS · SVRA · VSTM · XFOR · EYPT · VOR · HELP · MDWD DCTH · FENC · HELP · SVRA · REPL · VOR · MDWD · XFOR · AQST · PCVX

★ = latest filed quarter (predicted vs actual). Recall = share of the real Top 10 caught by the model; precision = share of the predicted Top 10 that were real.

Barra Factor Attribution

The disclosed long US equity book from the 2026-Q3 13F is held at its report-date weights and decomposed over 2026-09-30 ~ 2026-11-13. The model uses 16 Barra style factors plus GICS sector dummies, WLS cross-sectional factor returns and an EWMA factor covariance for risk. The “portfolio” is the visible 13F book, not the fund's true NAV.

13F periodQ3 2026 Attribution quarterQ4 2026 (in progress) Window2026-09-30 → 2026-11-13 Trading days32 Holdings3 Model coverage100.0%

The quarter is not complete yet; the window ends at the latest available price date, 2026-11-13, and will update as prices arrive.

Portfolio return-0.11%Buy & hold
QQQ synthetic benchmark-13.72%Liquidity weighted
Excess return+13.61%vs benchmark
Barra annualised vol28.7%Model estimate
Realised vol8.6%Annualised in window
Weighted beta1.04Raw exposure
Factor / specific risk68% / 32%Share of variance
Top-10 concentration100.0%Of reported value
Portfolio value (start = 100)78.485.091.798.3105.010-0110-2311-13Rosalind Advisors, Inc.QQQ syntheticLiquid universe EW
Start = 100. Red = portfolio, dark = QQQ synthetic benchmark, dashed grey = equal-weight model universe.

1. Performance

Metric Value Note
Portfolio return (buy & hold)-0.11%Disclosed long book
QQQ synthetic benchmark-13.72%Liquidity-weighted constituents
Model universe, equal weight+0.30%Opportunity-cost reference
Excess return+13.61%Portfolio − benchmark
Arithmetic return sum-0.06%Difference vs compounded is the cross term
Weighted raw beta1.04Weighted holding betas
Realised volatility (annualised)8.61%Daily returns in window
Barra model volatility (annualised)28.75%Factor + specific
Factor share of variance68.2%Barra factors
Specific share of variance31.8%Stock residuals
Reported value$365,20013F long US equity

2. Return attribution

The -0.06% arithmetic return splits into style factors, sector factors and specific return; the table is sorted by contribution.

Factor group Factors Contribution Share of |return|
Size & Liquidity 6 -0.11% -187.1%
Momentum & Growth 3 -0.14% -225.7%
Volatility & Tail Risk 7 +3.61% 5988.4%
Industry 12 +9.49% 15717.2%
Specific 1 -12.91% -21392.7%
Return attribution (style + industry, %)-10.9-5.4+0.0+5.4+10.9Growth+0.80Beta+0.88Mid Cap+1.04Leverage (Downside Vol)+1.22Turnover+1.38Skewness-1.59Kurtosis-1.69Non-linear Size+2.00Max Drawdown-2.00Health Care+2.40Residual Volatility-3.28Size-3.59Other+7.09Historical Volatility+10.07
Factor Type Exposure Factor return Contribution Share of |return|
Historical Volatility Style -0.78 -12.86% +10.07% 16689.4%
Other Industry +0.71 +10.06% +7.09% 11748.8%
Health Care Industry +0.29 +8.12% +2.40% 3968.5%
Non-linear Size Style +2.19 +0.91% +2.00% 3316.6%
Turnover Style -0.29 -4.77% +1.38% 2283.2%
Leverage (Downside Vol) Style -0.67 -1.82% +1.22% 2026.0%
Mid Cap Style -0.62 -1.69% +1.04% 1725.9%
Beta Style +0.18 +4.85% +0.88% 1455.2%
Growth Style +0.51 +1.57% +0.80% 1332.3%
Liquidity Style -1.14 +0.22% -0.24% -405.5%
Short-term Reversal Style -0.40 +0.79% -0.31% -514.8%
Momentum Style +0.19 -3.34% -0.63% -1043.2%
Amihud Illiquidity Style +1.74 -0.40% -0.70% -1161.3%
Skewness Style +0.38 -4.21% -1.59% -2627.8%
Kurtosis Style -0.24 +6.97% -1.69% -2799.6%
Max Drawdown Style +1.02 -1.96% -2.00% -3317.1%
Residual Volatility Style -1.23 +2.66% -3.28% -5438.0%
Size Style +1.96 -1.83% -3.59% -5945.9%
Specific Specific — — -12.91% -21392.7%

3. Risk attribution

Annualised volatility is 28.75%; factor risk explains 68.2% of variance and specific risk 31.8%. A negative variance contribution means the factor is negatively correlated with the rest of the book and acts as a partial hedge.

Risk attribution (share of variance, %)-39.8-19.9+0.0+19.9+39.8Skewness-1.49Non-linear Size-1.10Growth+1.44Mid Cap+1.63Historical Volatility+1.84Beta+2.09Size+2.78Liquidity+3.48Residual Volatility+4.16Leverage (Downside Vol)+5.36Amihud Illiquidity+5.66Health Care+6.36Specific+31.78Other+36.84
Factor Type Exposure Share of variance Vol contribution Share of vol
Other Industry +0.71 36.8% +10.59% 10.6%
Specific Specific — 31.8% +9.14% 9.1%
Health Care Industry +0.29 6.4% +1.83% 1.8%
Amihud Illiquidity Style +1.74 5.7% +1.63% 1.6%
Leverage (Downside Vol) Style -0.67 5.4% +1.54% 1.5%
Residual Volatility Style -1.23 4.2% +1.19% 1.2%
Liquidity Style -1.14 3.5% +1.00% 1.0%
Size Style +1.96 2.8% +0.80% 0.8%
Beta Style +0.18 2.1% +0.60% 0.6%
Historical Volatility Style -0.78 1.8% +0.53% 0.5%
Mid Cap Style -0.62 1.6% +0.47% 0.5%
Growth Style +0.51 1.4% +0.41% 0.4%
Momentum Style +0.19 0.3% +0.08% 0.1%
Turnover Style -0.29 -0.5% -0.14% -0.1%
Short-term Reversal Style -0.40 -0.6% -0.18% -0.2%
Non-linear Size Style +2.19 -1.1% -0.32% -0.3%
Skewness Style +0.38 -1.5% -0.43% -0.4%

4. Style exposures

Standardised z-scores; positive means the book leans toward that style versus the model universe, negative means underweight.

Style exposures (z-score)-1.6-0.50.51.52.5Max DrawdownKurtosisSkewnessLeverage (Downside Vol)GrowthTurnoverAmihud IlliquidityLiquidityHistorical VolatilityResidual VolatilityShort-term ReversalMomentumBetaMid CapNon-linear SizeSizePortfolioQQQ benchmark
Style factor Portfolio QQQ benchmark Difference
Size +1.96 +2.10 -0.14
Non-linear Size +2.19 +1.68 +0.51
Mid Cap -0.61 +0.13 -0.74
Beta +0.18 +1.29 -1.11
Momentum +0.19 +0.72 -0.53
Short-term Reversal -0.40 -0.64 +0.25
Residual Volatility -1.23 -0.40 -0.83
Historical Volatility -0.78 +0.86 -1.64
Liquidity -1.14 +0.11 -1.25
Amihud Illiquidity +1.74 +1.16 +0.58
Turnover -0.29 +0.21 -0.50
Growth +0.51 +0.58 -0.07
Leverage (Downside Vol) -0.67 +0.14 -0.82
Skewness +0.38 +0.24 +0.14
Kurtosis -0.24 +0.21 -0.46
Max Drawdown +1.02 -0.08 +1.11

5. Industry allocation & Brinson

Industry allocation (weight, %)-7.414.736.858.981.0Information TechnologyCommunication ServicesUtilitiesConsumer StaplesConsumer DiscretionaryIndustrialsHealth CareOtherPortfolioQQQ benchmark
Sector Portfolio Benchmark Portfolio ret Benchmark ret Allocation Selection Interaction Total
Information Technology 0.0% 73.6% +0.00% -19.18% +4.32% +14.12% -14.12% +14.12%
Other 70.5% 0.0% +2.69% +0.00% +9.38% +0.00% +1.90% +1.90%
Communication Services 0.0% 2.6% +0.00% -15.54% +0.06% +0.41% -0.41% +0.41%
Utilities 0.0% 0.8% +0.00% +11.58% -0.20% -0.09% +0.09% -0.09%
Consumer Staples 0.0% 0.8% +0.00% +15.58% -0.24% -0.13% +0.13% -0.13%
Consumer Discretionary 0.0% 8.8% +0.00% +5.56% -1.66% -0.49% +0.49% -0.49%
Industrials 0.0% 11.1% +0.00% +7.16% -2.27% -0.80% +0.80% -0.80%
Health Care 29.5% 1.7% -5.89% +9.16% +6.24% -0.26% -4.18% -1.90%
Total +15.53% +12.72% -15.27% +12.98%

6. Holdings & contribution

Symbol Name Sector Weight Return Contribution QoQ
QQQ INVESCO QQQ TR Other 70.51% +2.69% +1.90% New
BMY BRISTOL-MYERS SQUIBB CO Health Care 23.06% +2.70% +0.62% New
CORT CORCEPT THERAPEUTICS INC Health Care 6.44% -36.70% -2.36% New
Contribution rank Symbol Sector Weight Return Contribution
1 QQQ Other 70.51% +2.69% +1.90%
2 BMY Health Care 23.06% +2.70% +0.62%
3 CORT Health Care 6.44% -36.70% -2.36%

7. Conclusions

  1. Over the attribution window 2026-09-30 → 2026-11-13 (32 trading days), the reported portfolio returned -0.11%, versus -13.72% for the QQQ synthetic benchmark — an excess of +13.61%.
  2. Return attribution: the largest positive style/industry contributions came from Historical Volatility +10.07%, Other +7.09%, Health Care +2.40%; the largest drags came from Size -3.59%, Residual Volatility -3.28%, Max Drawdown -2.00%. Specific (stock-level) return contributed -12.91%.
  3. Risk attribution: Barra model volatility is 28.75% annualised; factor risk explains 68% of variance and specific risk 32%. The largest factor risk sources are Other 36.8%, Health Care 6.4%, Amihud Illiquidity 5.7%.
  4. Style tilt: size +1.96, momentum +0.19, volatility -0.78, liquidity -1.14; the weighted raw beta is 1.04. Positive z-scores mean the portfolio leans toward that style versus the cross-section.
  5. Industry: the largest overweight versus the benchmark is Other (+70.5 pp), the largest underweight is Information Technology (-73.6 pp). Allocation contributed +15.53%, selection +12.72% and interaction -15.27%.
  6. Concentration: the top-10 positions are 100.0% of the attributed portfolio and the model covers 100.0% of its value with full style exposures. This is a high-conviction, long-only 13F book — not the fund's complete NAV.
Methodology & caveats
  • 13F discloses long US equity (including some options) only; cash, shorts and non-US positions are absent. This is not the fund's true NAV.
  • Weights are the report-date reported values and stay fixed over the window (buy & hold); intra-quarter trading and flows are not captured.
  • Factor exposures are measured at quarter end and held through the next quarter; style factors are cross-sectionally orthogonalised and read as incremental exposures.
  • The database has no share-count data, so size and liquidity use dollar volume (price × volume) as a proxy; Size is closer to “traded-value scale”.
  • Factor returns come from a WLS cross-sectional regression on the model universe; risk is annualised, and some factor variance contributions can be negative.
  • 13F filings lag by up to 45 days, so the stretch from the report date to the filing date was not actionable in real time.
  • Sector mapping uses one consistent GICS level-1 scheme for both the portfolio and the benchmark.

FAQ

What did Rosalind Advisors, Inc. buy in 2026-Q3?

In its 2026-Q3 13F filing, Rosalind Advisors, Inc. reported 39 equity positions worth $244.66M in aggregate; its largest disclosed positions were DCTH ($52.71M), FENC ($33.95M), HELP ($17.06M).

How large is Rosalind Advisors, Inc.'s portfolio?

Rosalind Advisors, Inc. reported $244.66M of long equity holdings across 39 positions as of 2026-Q3. Top-10 holdings account for 74.5% of reported value.

What is Rosalind Advisors, Inc.'s investment style?

HoldingsHub classifies the portfolio as Small / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/rosalind-advisors/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →